---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021110"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:19:42.669008+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aquestive Therapeutics reports Q1 2024 results, FDA approval of Libervant, and progress on Anaphylm

## Summary
- Met all endpoints in Phase 3 pivotal study for Anaphylm (epinephrine) Sublingual Film compared to EpiPen and other injectors.
- Received FDA approval for Libervant (diazepam) Buccal Film in patients ages 2-5, now available in multiple strengths.
- Completed $77.5M underwritten public offering with institutional investors, extending cash runway into 2026.
- Total revenues increased to $12.1M in Q1 2024 from $11.1M in Q1 2023; net loss was $12.8M.
- On track to file Anaphylm NDA with FDA by end of 2024, with remaining studies expected by Q3 2024.

## SEC filing metadata
- accession: 0001628280-24-021110
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/aqst-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021110
- JSON: https://secwatch.observer/filing/0001628280-24-021110.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021110.txt

## Key facts
- Earnings Releases
  Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2024 and provided an update on recent developments in its business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.